Physician profile
Sharon Silverman
NPI 1144296328
$3,259.95
in general payments reported to CMS, 2019-2025
17 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.66 · 2020: $431 · 2021: $790 · 2022: $826 · 2023: $608 · 2024: $162 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.20 |
| Education | $101.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.69 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $319.76 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $312.36 | 2020-2023 | Seglentis, Livalo |
| Novo Nordisk INC | $262.20 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $251.71 | 2022 | |
| Allergan, INC. | $248.24 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $247.46 | 2021 | |
| Pfizer INC. | $241.80 | 2020-2025 | |
| Glaxosmithkline, LLC. | $218.67 | 2019-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $140.71 | 2019-2022 | |
| Astellas Pharma US INC | $140.63 | 2023 | Veozah |
| Exact Sciences Corporation | $65.20 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.81 | 2020 | |
| Eisai INC. | $34.10 | 2021 | |
| Abbott Laboratories | $33.68 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.72 | 2019-2022 | |
| Mylan Specialty L.P. | $22.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.